阿柏西普生物类似药治疗新生血管性年龄相关性黄斑变性的疗效与安全性:随机对照试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入6项3期随机对照试验(2022-2024年),共2029眼(生物类似药组1020眼,参照药组1009眼),比较阿柏西普生物类似药与参照阿柏西普在治疗初治新生血管性年龄相关性黄斑变性(nAMD)中的疗效与安全性。结果显示,第8周和第52周最佳矫正视力(BCVA)均无显著差异,且无患者获得≥15个字母比例、维持视力比例、中心亚 field 厚度(CST)变化及不良事件(AEs)的差异。结论表明,在按标签方案治疗下,生物类似药与参照药疗效和安全性相当,但真实世界中的延长耐久性尚未验证。
要点
- 阿柏西普生物类似药与参照药在nAMD治疗中第8周和第52周BCVA无显著差异。
- 患者获得≥15个字母比例、维持视力比例、CST变化及AEs均无显著差异。
- 证据确定性高,偏倚风险低,但真实世界延长给药间隔的耐久性未测试。
核心结论
- 在治疗初治nAMD眼按标签阿柏西普方案治疗下,阿柏西普生物类似药与参照阿柏西普在8周和52周疗效及安全性方面无显著差异。
- 真实世界中的延长耐久性尚未测试。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南并在PROSPERO注册(CRD4201069147)。
- 纳入6项3期随机对照试验(2022-2024年),共2029眼(生物类似药组1020眼,参照药组1009眼)。
- 所有研究采用标准化标签阿柏西普给药方案:初始3次每月负荷剂量后每8周注射一次。
主要发现
- 第8周BCVA平均差异(MD)为-0.34个字母(95%CI -1.12至0.44;I²=0%;p=0.39),组间无显著差异。
- 第52周BCVA的MD为-0.04(95%CI -1.18至1.10;I²=1%;p=0.94),组间无显著差异。
- 患者获得≥15个字母比例、维持视力比例、CST变化及AEs均无差异。
关键数值与推荐
- 主要结局为第8周BCVA的平均差异(MD)。
- 次要结局包括第52周BCVA、获得≥15个字母或维持视力(<15个字母丢失)的患者比例、中心亚 field 厚度(CST)及不良事件(AEs)。
临床怎么用
- 在治疗初治nAMD且按标签阿柏西普方案治疗时,阿柏西普生物类似药可作为参照阿柏西普的替代选择,疗效和安全性相当。
- 临床使用时需注意真实世界延长给药间隔的耐久性尚未验证。
局限性
- 真实世界中的延长耐久性尚未测试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate the efficacy and safety of aflibercept biosimilars compared with reference aflibercept in the treatment of neovascular age-related macular degeneration (nAMD). METHODS: A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered on PROSPERO (CRD4201069147). Phase 3 randomised controlled trials (RCTs) comparing aflibercept biosimilars to reference aflibercept in treatment-naïve nAMD were included. All included studies employed a standardised on-label aflibercept dosing regimen consisting of three initial monthly loading doses followed by injections every 8 weeks. The primary outcome was the mean difference (MD) in best-corrected visual acuity (BCVA) at week 8. Secondary outcomes included BCVA at week 52, proportion of patients gaining ≥15 letters or maintaining vision (<15-letter loss), central subfield thickness (CST) and adverse events (AEs). RESULTS: Six RCTs (2022-2024) were included, comprising 2029 eyes (1020 biosimilar; 1009 reference). BCVA at week 8 did not differ significantly between groups (MD -0.34 letters; 95% CI -1.12 to 0.44; I²=0%; p=0.39), as was BCVA at week 52 (MD -0.04; 95% CI -1.18 to 1.10; I²=1%; p=0.94). No differences were observed in the proportion of patients gaining ≥15 letters, maintaining vision, CST changes or AEs. CONCLUSIONS: Aflibercept biosimilars demonstrated no significant difference in efficacy at 8 weeks and 52 weeks as well as safety relative to reference aflibercept in eyes with treatment-naïve nAMD following an on-label aflibercept treatment protocol; however, real-world extended durability remains untested. These findings were supported by a low risk of bias and a high-certainty of evidence using the Grading of Recommendations, Assessment, Development and Evaluations tool.
引用
- Zhang C, Sonik NR, Ayoubi M, et al. Clinical efficacy and safety of aflibercept biosimilars in neovascular age-related macular degeneration: a systematic review and meta-analysis of randomised controlled trials. Br J Ophthalmol. 2026. PMID: 42236129. doi:10.1136/bjo-2025-328196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。